Quarterly report pursuant to Section 13 or 15(d)

Investments - Narrative (Details)

v3.21.2
Investments - Narrative (Details) - USD ($)
$ in Thousands
1 Months Ended 6 Months Ended 12 Months Ended
Aug. 31, 2020
Jun. 30, 2021
Dec. 31, 2020
Apr. 30, 2013
Schedule of Equity Method Investments [Line Items]        
Total assets of equity method investees   $ 2,421,650 $ 2,473,063  
Total liabilities of equity method investees   679,065 801,512  
Market value   7,100    
Equity Method Investment, Nonconsolidated Investee or Group of Investees        
Schedule of Equity Method Investments [Line Items]        
Total assets of equity method investees   179,000 90,900  
Total liabilities of equity method investees   26,700 28,400  
Net losses of equity method investees   $ 5,900 $ 75,400  
Pharmsynthez        
Schedule of Equity Method Investments [Line Items]        
Ownership percentage, equity method   9.00%   9.00%
Cocrystal        
Schedule of Equity Method Investments [Line Items]        
Ownership percentage, equity method   3.00%    
Number of shares into which warrants may be converted (in shares)   33,000    
Non-Invasive Monitoring Systems, Inc.        
Schedule of Equity Method Investments [Line Items]        
Ownership percentage, equity method   1.00%    
Neovasc        
Schedule of Equity Method Investments [Line Items]        
Ownership percentage, equity method   1.00%    
InCellDx, Inc        
Schedule of Equity Method Investments [Line Items]        
Ownership percentage, equity method   29.00%    
Number of shares into which warrants may be converted (in shares)   700,000    
BioCardia, Inc.        
Schedule of Equity Method Investments [Line Items]        
Ownership percentage, equity method   1.00%    
Ownership percentage   1.00%    
Number of shares into which warrants may be converted (in shares)   47,000    
Xenetic Biosciences, Inc.        
Schedule of Equity Method Investments [Line Items]        
Ownership percentage, equity method   2.00%    
Number of shares into which warrants may be converted (in shares)   40,000    
Phio Pharmaceuticals        
Schedule of Equity Method Investments [Line Items]        
Ownership percentage   0.01%    
Number of shares into which warrants may be converted (in shares)   404    
VBI Vaccines Inc        
Schedule of Equity Method Investments [Line Items]        
Ownership percentage   1.00%    
ChromaDex        
Schedule of Equity Method Investments [Line Items]        
Ownership percentage   0.10%    
Eloxx Pharmaceuticals        
Schedule of Equity Method Investments [Line Items]        
Ownership percentage   2.00%    
Detect Genomix | Variable Interest Entity, Not Primary Beneficiary        
Schedule of Equity Method Investments [Line Items]        
Ownership percentage, equity method 49.00%      
Additional investment in equity method investment $ 245      
Zebra | Variable Interest Entity, Not Primary Beneficiary        
Schedule of Equity Method Investments [Line Items]        
Ownership percentage, equity method   29.00%    
Series A Preferred Stock | Zebra | Variable Interest Entity, Not Primary Beneficiary        
Schedule of Equity Method Investments [Line Items]        
Investment owned (in shares)   1,260,000    
Restricted Stock | Zebra | Variable Interest Entity, Not Primary Beneficiary        
Schedule of Equity Method Investments [Line Items]        
Shares received as a gift (in shares)   900,000